Publication | Closed Access

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Neuro-oncologyGliomaMedicineStandard TreatmentPathologyAnti-cancer AgentHigh-grade GliomasMethylated Mgmt PromoterCancer TreatmentOncologyRadiation OncologyMolecular Oncology